Hospital-acquired Bacterial Pneumonia

• EMA approval · 2026-01-26
  EMA Authorised: Recarbrio (imipenem monohydrate;cilastatin sodium;relebactam monohydrate) — Merck Sharp & Dohme B.V.

  EMA authorised Recarbrio (imipenem/cilastatin/relebactam) for use in Gram-negative bacterial infections, including hospital-acquired/ventila…

• FDA approval · 2020-07-07
  FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)

  FDA approved a supplemental application for VIBATIV (telavancin hydrochloride) submitted by Cumberland Pharmaceuticals Inc. The action updat…

• FDA approval · 2014-03-13
  FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)

  FDA approved a supplemental labeling application for VIBATIV (telavancin hydrochloride) submitted by Cumberland Pharmaceuticals. The approva…

• FDA approval · 2013-12-12
  FDA Approved: VIBATIV — Supplemental Application (Cumberland Pharmaceuticals Inc.)

  FDA approved a supplemental application for Vibativ (telavancin hydrochloride) from Cumberland Pharmaceuticals Inc.

• FDA approval · 2009-09-11
  FDA Approved: VIBATIV — Original Application (Cumberland Pharmaceuticals Inc.)

  FDA approved Vibativ (telavancin hydrochloride) through an original NDA for the treatment of hospital-acquired bacterial pneumonia and compl…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.